ArticleOncoTargets and therapy2018
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
Shun Lu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this paperpooled itcites it